140 related articles for article (PubMed ID: 21474042)
1. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice.
Merki E; Graham M; Taleb A; Leibundgut G; Yang X; Miller ER; Fu W; Mullick AE; Lee R; Willeit P; Crooke RM; Witztum JL; Tsimikas S
J Am Coll Cardiol; 2011 Apr; 57(15):1611-21. PubMed ID: 21474042
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
3. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
[TBL] [Abstract][Full Text] [Related]
4. Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma.
Yamamoto T; Obika S; Nakatani M; Yasuhara H; Wada F; Shibata E; Shibata MA; Harada-Shiba M
Eur J Pharmacol; 2014 Jan; 723():353-9. PubMed ID: 24269597
[TBL] [Abstract][Full Text] [Related]
5. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
Tsimikas S; Brilakis ES; Miller ER; McConnell JP; Lennon RJ; Kornman KS; Witztum JL; Berger PB
N Engl J Med; 2005 Jul; 353(1):46-57. PubMed ID: 16000355
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
7. Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)
Marcovina SM; Viney NJ; Hughes SG; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(1):122-129.e2. PubMed ID: 29174389
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models.
Boffa MB; Marcovina SM; Koschinsky ML
Clin Biochem; 2004 May; 37(5):333-43. PubMed ID: 15087247
[TBL] [Abstract][Full Text] [Related]
10. Testing for apolipoprotein(a) phenotype using isoelectric focusing and immunoblotting technique.
Langer C; Tambyrayah B; Nowak-Göttl U
Methods Mol Biol; 2013; 992():407-12. PubMed ID: 23546733
[TBL] [Abstract][Full Text] [Related]
11. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
[TBL] [Abstract][Full Text] [Related]
12. The oxidized phospholipids linked to human apolipoprotein(a) do not derive from circulating low-density lipoproteins and are probably of cellular origin.
Edelstein C; Philips B; Pfaffinger D; Scanu AM
FASEB J; 2009 Mar; 23(3):950-6. PubMed ID: 19001055
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms and significance of lipoprotein(a) in hepatocellular carcinoma.
Jiang JT; Wu CP; Xu N; Zhang XG
Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):25-8. PubMed ID: 19208510
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
van Vlijmen BJ; Pearce NJ; Bergö M; Staels B; Yates JW; Gribble AD; Bond BC; Hofker MH; Havekes LM; Groot PH
Arzneimittelforschung; 1998 Apr; 48(4):396-402. PubMed ID: 9608883
[TBL] [Abstract][Full Text] [Related]
15. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice.
Yu XX; Murray SF; Watts L; Booten SL; Tokorcheck J; Monia BP; Bhanot S
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E436-45. PubMed ID: 18523126
[TBL] [Abstract][Full Text] [Related]
16. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a).
Dieplinger H; Lackner C; Kronenberg F; Sandholzer C; Lhotta K; Hoppichler F; Graf H; König P
J Clin Invest; 1993 Feb; 91(2):397-401. PubMed ID: 8432847
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein analysis in transgenic mice expressing human apolipoprotein (apo) A-I and apo C III: use of micromethods in analysis of lipoprotein system in mice.
Ito Y
Hokkaido Igaku Zasshi; 1994 Mar; 69(2):312-26. PubMed ID: 8157256
[TBL] [Abstract][Full Text] [Related]
18. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study.
Bakris GL; Smith AC; Richardson DJ; Hung E; Preston R; Goldberg R; Epstein M
J Hum Hypertens; 2002 Mar; 16(3):185-91. PubMed ID: 11896508
[TBL] [Abstract][Full Text] [Related]
19. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
20. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.
Graham MJ; Viney N; Crooke RM; Tsimikas S
J Lipid Res; 2016 Mar; 57(3):340-51. PubMed ID: 26538546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
